Delivery of Denosumab via Hollow Microneedle

Abstract

The emergence of transdermal drug delivery via hollow microneedle can be used to enhance the distribution of medications delivered through the skin. In this current study, in-vivo animal studies of denosumab were carried out which involved the use of hollow microneedle to draw a comparison with the painful injection for the treatment of osteoporosis. The in-vivo study of the hollow-microneedle mediated delivery of denosumab, a monoclonal antibody was conducted to investigate if there is any possibility of improvement in osteoporosis, which affects a significant segment of post-menopausal women. Hollow microneedles mediated denosumab deliveries showed a remarkable improvement as compared to traditional injections. In recent times, hollow microneedle has managed to receive special attention as a novel drug delivery system due to its nature of being minimally invasive across the skin. In conclusion, the hollow microneedles may prove to be of great assistance for widening the feasibility of delivery of a wide range of therapeutic entities.